Aradigm Corporation Files Request For Orphan Drug Designation For Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis

Aradigm Corporation (NASDAQ: ARDMD) today announced that it has filed a request for orphan drug designation with the United States Food and Drug Administration (FDA) for its liposomal ciprofloxacin product for the management of cystic fibrosis (CF).